PDCD1 and neoplasm: Nevertheless, results from KEYNOTE 183 (pomalidomide + dexamethasone + pembrolizumab) and KEYNOTE 185 (lenalidomide + dexamethasone + pembrolizumab) suggested that anti PD-1 mAbs are more effective in patients with activation of the immune system as MMD; however, it remains to clarify which is the best combination, dose and regimen to avoid the toxicity and increase the anti-tumor effect of these class of agents.